Medicenna Therapeutics (TSE:MDNA – Get Free Report) released its quarterly earnings results on Monday. The company reported C($0.04) EPS for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 360.29%.
Medicenna Therapeutics Price Performance
MDNA opened at C$0.36 on Tuesday. The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65. The company has a market capitalization of C$33.69 million, a price-to-earnings ratio of -1.66 and a beta of 2.49. The firm’s fifty day moving average price is C$0.42 and its two-hundred day moving average price is C$0.53. Medicenna Therapeutics has a 1 year low of C$0.34 and a 1 year high of C$1.78.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Read More
- Five stocks we like better than Medicenna Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
